Challenging the Use of the US Special 301 Procedures against Measures Promoting Access to Medicines - Options under the WTO Agreements

Journal of International Economic Law, Volume 19, Issue 1, March 2016, Pages 51-86, DOI: 10.1093/jiel/jgw004

33 Pages Posted: 19 Oct 2015 Last revised: 29 Apr 2018

See all articles by Suzanne Zhou

Suzanne Zhou

McCabe Centre for Law & Cancer; University of Cambridge - Trinity Hall; University of Melbourne

Date Written: September 1, 2015

Abstract

In April 2014, the United States Trade Representative (USTR) listed India on its Special 301 Priority Watch List, following India’s refusal to grant a patent over the leukemia drug Gleevec and its compulsory licensing of the cancer drug Nexavar. USTR also undertook an out-of-cycle review of India’s intellectual property laws, to determine whether or not to upgrade India to the more serious Priority Foreign Country status, which would potentially trigger retaliation through withdrawal of GSP benefits. In response, India threatened to take the United States to the World Trade Organization’s Dispute Settlement Body over Special 301. This article examines whether such a challenge to Special 301 in the WTO would succeed, both in the India context and more generally. It takes three lines of inquiry. The first is whether or not the Special 301 procedure violates the procedural obligations under article 23 of the Dispute Settlement Understanding (DSU). The second is whether or not any related withdrawal of GSP benefits would be in line with the Enabling Clause. Finally, the article examines whether there are substantive limitations on intellectual property protections under TRIPS which could be used to challenge the validity of Special 301. It concludes that some, but not all, aspects of Special 301 may be inconsistent with WTO obligations.

Keywords: Special 301, access to medicines, patents, World Trade Organization, TRIPS

JEL Classification: K33, K32

Suggested Citation

Zhou, Suzanne, Challenging the Use of the US Special 301 Procedures against Measures Promoting Access to Medicines - Options under the WTO Agreements (September 1, 2015). Journal of International Economic Law, Volume 19, Issue 1, March 2016, Pages 51-86, DOI: 10.1093/jiel/jgw004 . Available at SSRN: https://ssrn.com/abstract=2675990 or http://dx.doi.org/10.2139/ssrn.2675990

Suzanne Zhou (Contact Author)

McCabe Centre for Law & Cancer ( email )

615 St Kilda Road
Melbourne, Victoria 3004
Australia

University of Cambridge - Trinity Hall ( email )

Trinity Lane
Cambridge, CB2 1TJ
United Kingdom

University of Melbourne ( email )

185 Pelham Street
Carlton, Victoria 3053
Australia

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
101
Abstract Views
577
rank
281,209
PlumX Metrics